login
  Password reminder
Cardiovascular News
Contact the editor Visit Cardiovascular News Twitter feed Visit Cardiovascular News Facebook page
 

First patient treated in Japan with Abbott’s Absorb BVS


Friday, 19 Aug 2011 15:19
Absorb bioresorbable vascular scaffold
Absorb bioresorbable vascular scaffold


The first patient in Japan has been treated with Abbotts’ Absorb bioresorbable vascular scaffold (BVS) as part of the ABSORB EXTEND global clinical trial. To date, more than 300 patients in Europe, Latin America and Asia Pacific have been enrolled in this trial.


Absorb restores blood flow by opening a clogged vessel and providing support to the vessel until the device dissolves within approximately two years, leaving patients with a treated vessel free of a permanent metallic implant.


The first patient in Japan was treated in the ABSORB EXTEND clinical trial by Shigeru Saito, director, Cardiology and Catheterization Laboratories, and vice president, Shonan Kamakura Hospital, Kanagawa, Japan.


“Abbott’s BVS technology has the potential to open up a new therapy option for physicians treating patients with coronary artery disease in Japan,” said Saito. “For Japanese patients, this technology will hold tremendous appeal, as it is designed to treat a clogged blood vessel like a drug eluting stent and then dissolve, thereby restoring a more natural vessel function without leaving a permanent metallic implant behind in the body. Our hope is that our participation in the ABSORB EXTEND trial will be a meaningful contribution toward making this innovative technology available to patients in Japan.”


Absorb is made of polylactide, a proven biocompatible material that is commonly used in medical implants such as dissolving sutures. Because a permanent metallic implant is not left behind, a vessel treated with this device may ultimately have the ability to move, flex, pulsate and dilate. Restoration of these naturally occurring vessel functions is one of the features that makes this device a significant innovation for patients in the evaluation and treatment of coronary artery disease. In addition, continuing research will show whether the need to administer long-term dual anti-platelet therapy to patients is necessary once the temporary scaffold is metabolised.


The Absorb BVS received CE mark approval for the treatment of coronary artery disease and is under clinical investigation in several countries around the world.


About the ABSORB EXTEND clinical trial


The ABSORB EXTEND trial is a large-scale, single-arm trial that will enrol approximately 1,000 patients with complex coronary artery disease at up to 100 centres in Europe, Asia Pacific, Canada and Latin America.


Data from this trial may be used to support approval in various markets around the world. Key endpoints of the study include assessments of safety - major adverse cardiac events (MACE) and treated-site thrombosis rates - at 30 days and at six, 12, 24 and 36 months, as well as an assessment of the acute performance of the bioresorbable vascular scaffold, including successful deployment of the system. Other key endpoints in a sub-group study include imaging assessments by angiography, intravascular ultrasound (IVUS), optical coherence tomography (OCT), and other imaging modalities.




Add New Comment

Related Items


Most popular


Medtronic initiates study evaluating potential of combination of pulmonary vein isolation and renal denervation for atrial fibrillation
Friday, 01 May 2015
Medtronic has announced the start of a clinical study using Medtronic technologies to determine whether paroxysmal and persistent atrial fibrillation can be treated with a combination of two ablation ... Medtronic initiates study evaluating potential of combination of pulmonary vein isolation and renal denervation for atrial fibrillation

First patient enrolled in Vessix sham-controlled study
Friday, 17 Apr 2015
Boston Scientific has announced that it is taking a new approach to evaluate the performance of its Vessix renal Denervation System. It says it is initiating a study with a novel design to isolate ... First patient enrolled in Vessix sham-controlled study

CardioCel to feature at prominent heart valve conferences
Wednesday, 01 Apr 2015
Admedus’ CardioCel will be featured in a number of presentations at the American Association for Thoracic Surgery Mitral Conclave 2015 meeting and the 95th AATS Annual Meeting. CardioCel to feature at prominent heart valve conferences

Features


Non-invasive FFRCT could transform management of coronary artery disease
Friday, 29 May 2015
Daniel Simon reviews a new system that simulates fractional flow reserve (FFR) measurements using computed tomography (FFRCT, HeartFlow). He explains why he believes this system, which recently ... Non-invasive FFRCT could transform management of coronary artery disease

Tips and tricks for achieving optimum results with a drug-coated balloon
Thursday, 07 May 2015
With drug-coated balloons, we may have been able to deliver a device to the lesion, but we were not always sure how much drug we actually delivered. Fortunately, because of this problem, there have ... Tips and tricks for achieving optimum results with a drug-coated balloon

Profiles


Flavio Ribichini
Thursday, 05 Mar 2015
Flavio Ribichini speaks to Cardiovascular News about being involved in the first use of primary ... Flavio Ribichini

Sunil Rao
Thursday, 23 Oct 2014
Sunil Rao speaks to Cardiovascular News about his career highlights, including his research into ... Sunil Rao

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
 
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions